(773) 977-7142 (773) 977-7145
Our eyes change with age, so regular checkups are a must. Because many people are affected by chronic eye conditions, stem cell therapy is now an option. If you have been living with a debilitating eye condition for a while, consider stem cell therapy options.
Many ophthalmological conditions are the result of damaged nerves or inflammation. The goal of stem cell therapy is to stimulate the growth of new cell tissues and replace dead cell tissues. Ophthalmologic conditions being studied with stem cell therapy include:
Loss of retinal neurons causes permanent blindness because lost photoreceptors and ganglion cells are not replaced when axons fail to regenerate. Stem cell therapies can be used to restore lost visual system connectivity in retinal degenerative disease. The stem cell therapy we use for retinal degeneration are the stem cells from sources outside the retina (mesenchymal stem cells or MSCs.
According to recent clinical studies, adipose-derived stem cells and bone marrow stem cells provided support for neuroprotection and axon regeneration of damaged retinal cells. This was done directly through secretion of certain neurotrophic factors, as well as indirectly, possibly by stimulating endogenous retinal cells which provided paracrine support and replaced damaged cells. Neural stem cells were found to provide neuroprotection and replacement of retinal neurons.
The use of adipose-derived stem cells (ADSCs) is simple and convenient. Recent research into ADSCs has shown that stem cells are more prevalent in fat tissue than in muscle or other organs. Many disorders that respond to stem cell treatment do so in a dose-dependent manner, meaning the more stem cells that can be harvested the better the chances of recovery.
The Cell Surgical Network investigates the use of autologous adipose derived stromal fraction, which has been shown to contain pre-adipocytes, peri-vascular, and hematopoietic stem cells. Therapy and research is conducted under IRB-approved protocols.
The approved protocol for harvesting ADSCs from patients yields 10 million – 40 million stem cells.
Kamao H, Mandai M, Okamoto S, et al. (2014). Characterization of Human Induced Pluripotent Stem Cell–Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application. Stem Cell Research, 2, 205-218.
Mead B, Berry M, Logan A, et al. (2015). Stem cell treatment of degenerative eye disease. Stem Cell Research, 14(3), 243-257.